CoChat
Sign Up
Cited by 314Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial

Coric, Vladimir, Taskiran, Sarper, Pittenger, Christopher, Wasylink, Suzanne, Mathalon, Daniel H., Valentine, Gerald, Saksa, John, Wu, Yu-te +4 more·2005·Biological Psychiatry
DOI 10.1016/j.biopsych.2005.04.043
Open this paper in CoChat — free account

Abstract

Background Most patients with obsessive-compulsive disorder (OCD) show only partial reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD.Methods Thirteen patients aged between 18 and 65 years with a primary diagnosis of OCD that had proven resistant to standard treatment were treated with the addition of riluzole to their existing pharmacotherapy. Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Inventory (HAM-D), and Hamilton Anxiety Inventory (HAM-A) scores were obtained weekly.Results Thirteen treatment-resistant OCD patients received riluzole 50 mg twice a day. Y-BOCS scores improved significantly over time. Of 13 patients, 7 (54%) demonstrated a >35% reduction in Y-BOCS scores, and 5 (39%) were categorized as treatment responders. HAM-D and HAM-A scores for the group also significantly improved over time. Riluzole was well tolerated with no serious adverse effects noted.Conclusions Riluzole appears to have significant antiobsessional, antidepressant, and antianxiety properties. The addition of this agent may be of practical clinical benefit in patients with OCD.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2005.04.043

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BDZs exhibit rapid anxiolytic effects, but also have sedative, amnestic, anticonvulsant, muscle relaxant and addictive properties.

    “BDZs, which have been in clinical use for decades, not only exhibit rapid anxiolytic effects, but also have sedative, amnestic, anticonvulsant, muscle relaxant and addictive properties (Coric et al., 2005;Engin et al., 2018).”

    From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Coric et al., 2005

  • Riluzole reduces clinical symptoms in adults with treatment-refractory OCD when used as add-on to existing pharmacotherapy including SSRIs and antipsychotics.

    “Riluzole was shown to reduce clinical symptoms in adults with treatment-refractory OCD when used as add-on to existing pharmacotherapy, including SSRIs and antipsychotics (Coric et al., 2005;Pittenger et al., 2015).”

    From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Coric et al., 2005

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., Malison, R. T., & Krystal, J. H.
Affiliations
Yale University (US)
ORCID
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2005-09
Volume
58
Issue
5
Pages
424-428
ISSN
0006-3223 (ISSN-L)
DOI
10.1016/j.biopsych.2005.04.043
OpenAlex
W1982538263
Cited by
314
References
25
Citations by year
2026: 7 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 5 · 2017: 15 · 2016: 15 · 2015: 21 · 2014: 21 · 2013: 22 · 2012: 23
FWCI
25.07
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k05aa014906-03)
  • National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01)
  • National Center for Research Resources (M01RR000125, M01 RR-00125)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords
riluzole, treatment-resistant OCD, augmentation therapy, glutamate modulation, glutamatergic dysfunction, corticostriatal pathway, antidepressant effects, anxiolytic effects, adverse effects
MeSH terms
Adult, Drug Resistance, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Time Factors, Treatment Outcome, Excitatory Amino Acid Antagonists, Riluzole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review